EyePoint Pharmaceuticals Files 8-K
Ticker: EYPT · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-disclosure, filing
Related Tickers: EYPT
TL;DR
EYPT filed a routine 8-K, confirming its Nasdaq listing and HQ address.
AI Summary
EyePoint Pharmaceuticals, Inc. filed an 8-K on January 13, 2025, reporting its status as a public company. The filing confirms its principal executive offices are located at 480 Pleasant Street, Watertown, Massachusetts, 02472, and its common stock trades on The Nasdaq Global Market under the symbol EYPT.
Why It Matters
This filing serves as a standard corporate disclosure, confirming the company's operational details and stock exchange listing.
Risk Assessment
Risk Level: low — This is a routine filing that does not contain new material financial or operational information.
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- 480 Pleasant Street, Watertown, Massachusetts, 02472 (location) — Address of Principal Executive Offices
- EYPT (ticker) — Trading Symbol
- The Nasdaq Global Market (exchange) — Name of exchange on which registered
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is a Current Report filed by EyePoint Pharmaceuticals, Inc. to report information that may be of interest to its shareholders and the public, such as the date of the earliest event reported and its principal executive offices.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 13, 2025.
Where are EyePoint Pharmaceuticals, Inc.'s principal executive offices located?
EyePoint Pharmaceuticals, Inc.'s principal executive offices are located at 480 Pleasant Street, Watertown, Massachusetts, 02472.
On which exchange is EyePoint Pharmaceuticals, Inc. common stock traded?
EyePoint Pharmaceuticals, Inc. common stock is traded on The Nasdaq Global Market.
What is the trading symbol for EyePoint Pharmaceuticals, Inc. common stock?
The trading symbol for EyePoint Pharmaceuticals, Inc. common stock is EYPT.
Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-01-13 07:05:23
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind
Filing Documents
- eypt-20250113.htm (8-K) — 43KB
- eypt-ex99_1.htm (EX-99.1) — 31KB
- eypt-ex99_2.htm (EX-99.2) — 43KB
- img97631278_0.jpg (GRAPHIC) — 97KB
- eypt-ex99_1s1.jpg (GRAPHIC) — 210KB
- eypt-ex99_1s2.jpg (GRAPHIC) — 713KB
- eypt-ex99_1s3.jpg (GRAPHIC) — 431KB
- eypt-ex99_1s4.jpg (GRAPHIC) — 363KB
- eypt-ex99_1s5.jpg (GRAPHIC) — 266KB
- eypt-ex99_1s6.jpg (GRAPHIC) — 391KB
- eypt-ex99_1s7.jpg (GRAPHIC) — 324KB
- eypt-ex99_1s8.jpg (GRAPHIC) — 439KB
- eypt-ex99_1s9.jpg (GRAPHIC) — 213KB
- eypt-ex99_1s10.jpg (GRAPHIC) — 337KB
- eypt-ex99_1s11.jpg (GRAPHIC) — 365KB
- eypt-ex99_1s12.jpg (GRAPHIC) — 360KB
- eypt-ex99_1s13.jpg (GRAPHIC) — 318KB
- eypt-ex99_1s14.jpg (GRAPHIC) — 335KB
- eypt-ex99_1s15.jpg (GRAPHIC) — 198KB
- eypt-ex99_1s16.jpg (GRAPHIC) — 414KB
- eypt-ex99_1s17.jpg (GRAPHIC) — 349KB
- eypt-ex99_1s18.jpg (GRAPHIC) — 320KB
- eypt-ex99_1s19.jpg (GRAPHIC) — 216KB
- eypt-ex99_1s20.jpg (GRAPHIC) — 407KB
- eypt-ex99_1s21.jpg (GRAPHIC) — 270KB
- eypt-ex99_1s22.jpg (GRAPHIC) — 319KB
- eypt-ex99_1s23.jpg (GRAPHIC) — 356KB
- eypt-ex99_1s24.jpg (GRAPHIC) — 354KB
- eypt-ex99_1s25.jpg (GRAPHIC) — 433KB
- eypt-ex99_1s26.jpg (GRAPHIC) — 377KB
- eypt-ex99_1s27.jpg (GRAPHIC) — 190KB
- eypt-ex99_1s28.jpg (GRAPHIC) — 492KB
- eypt-ex99_1s29.jpg (GRAPHIC) — 428KB
- eypt-ex99_1s30.jpg (GRAPHIC) — 207KB
- 0000950170-25-004557.txt ( ) — 14687KB
- eypt-20250113.xsd (EX-101.SCH) — 23KB
- eypt-20250113_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 13, 2025, EyePoint Pharmaceuticals, Inc. (the "Company") posted an updated investor presentation on its website at www.eyepointpharma.com which includes certain financial information as of December 31, 2024. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
01 Other Events
Item 8.01 Other Events. On the same date, the Company issued a press release summarizing its 2025 clinical plans and highlighting recent corporate and clinical achievements. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated by reference herein. The information set forth in Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 99.2 Investor Presentation of EyePoint Pharmaceuticals, Inc. dated January 13, 2025 Press Release of EyePoint Pharmaceuticals, Inc. dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: January 13, 2025 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer